论文部分内容阅读
目的比较柔红霉素联合阿糖胞苷骨髓腔给药诱导缓解急性非淋巴细胞白血病(简称急非淋)的疗效和不良反应。方法用随机对照的方法将60例初治急非淋患者分为骨髓腔给药组(A组,30例)和静脉给药组(B组,30例)。观察两组的疗效和不良反应。结果A组与B组完全缓解率分别为70.0%、33.3%。总有效率分别为86.7%、50.0%。A组比B组高,差异均有统计学意义(P<0.05)。不良反应:A组心脏毒性、胃肠道反应发生率比B组低,差异有统计学意义(P<0.05)。A组与B组骨髓抑制发生率相近,差异无统计学意义(P>0.05)。结论骨髓腔给药诱导缓解急非淋有较高的缓解率和较低的毒副反应。
Objective To compare the efficacy and side effects of daunorubicin and cytarabine in the treatment of acute non-lymphocytic leukemia (ADR). Methods Sixty naive acute non-lymphoid patients were divided into three groups: group A (n = 30) and group B (n = 30) by randomized controlled trial. The efficacy and adverse reactions of the two groups were observed. Results The complete remission rates of group A and group B were 70.0% and 33.3% respectively. The total effective rate was 86.7%, 50.0%. A group than B group, the difference was statistically significant (P <0.05). Adverse reactions: A group of cardiac toxicity, gastrointestinal reactions than the B group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of bone marrow suppression between group A and group B (P> 0.05). Conclusion Intramedullary cavity administration induces amelioration of urgency and non-lymphadenopathy with high remission rate and low toxicity.